Introduction: There is limited data on mortality and associated morbidity in non-cystic fibrosis bronchiectasis (NCFB). Our aim was to analyze the overall mortality for all newly diagnosed patients from June 2006 onwards and to evaluate risk factors for mortality in this cohort. Methods: 245 patients who had a new diagnosis of NCFB between June 2006 and October 2012 at the University Hospital of Leuven, Belgium, were included in the analysis. Death was analyzed until end of November 2013. All patients had chest HRCT scan confirming the presence of bronchiectatic lesions and had symptoms of chronic productive cough. Univariate and multivariate Cox proportional hazard survival regression analysis was used to estimate hazard ratios (HR) and their 95% confidence intervals (CI) of variables possibly predicting mortality. Results: Overall mortality in NCFB patients who had a median follow-up of 5.18 years was 20.4%. Patients with NCFB and associated chronic obstructive pulmonary disease (COPD) had a mortality of 55% in that period. Univariate analysis showed higher mortality according to age, gender, smoking history, Pseudomonas aeruginosa status, spirometry, radiological extent, total number of sputum bacteria and underlying etiology. Multivariate analysis showed significant higher mortality with increasing age (HR Z 1.045; p Z 0.004), with increasing number of lobes affected (HR Z 1.53; p Z 0.009) and when patients had COPD associated NCFB (HR Z 2.12; p Z 0.038). The majority of the 50 deaths were respiratory related (n Z 29; 58%). E-mail address: pieter.goeminne@student.kuleuven.be (P.C. Goeminne). Conclusion: NCFB patients with associated COPD disease had the highest mortality rates compared to the other NCFB patients. Additional risk factors for lower survival were increasing age and number of lobes affected. ª
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Background
Bronchiectasis is defined as permanently dilated airways due to chronic bronchial inflammation caused by inappropriate clearance of various microorganisms and recurrent or chronic infection [1] . With the exception of cystic fibrosis (CF), there is a lack of research into bronchiectasis. Recently, De Soyza et al. proposed several research priorities in non-cystic fibrosis bronchiectasis (NCFB). They state that from an epidemiological point of view, more prospective data are needed on mortality and associated morbidity [2] .
Several retrospective analyses have already been performed. In England and Wales, just under 1000 people die from bronchiectasis with the number increasing 3% per year [3] . In a hospital setting, mainly older age (>65 years), male gender, smoking history, mechanical ventilation, socioeconomic status (SES) and lower lung function show higher mortality [4e7]. In a cross-sectional retrospective analysis of patients known with a radiological diagnosis of bronchiectasis (including asymptomatic interstitial lung disease and thoracic tumor patients), we previously showed a 41-month death rate of 10.6% [8] . These data are in line with the long term prospective analysis by Loebinger et al. They found that over a 13-year period, 29.7% of the 91 patients died, and male gender, older age, lung function and Pseudomonas aeruginosa (PA) were correlated with higher mortality [9] . Another prospective analysis from Turkey showed an even poorer outcome with 4-year survival of only 58%. They suggest that the presence of hypoxemia, hypercapnia, dyspnea levels and radiographic extent lead to higher mortality [10] .
Our primary aim was to analyze the overall mortality for all newly diagnosed patients from June 2006 onwards. We assessed the known risk factors such as age, gender, smoking history, number of lobes affected, type of bronchiectasis and PA and evaluated the impact on mortality of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin and other long-term antibiotic use and presence/development of pulmonary hypertension (PH).
Materials and methods

Patient selection
Patients who had a new diagnosis of bronchiectasis between June 2006 and October 2012 at the University Hospital of Leuven, Belgium, were included in the analysis. Death was analyzed until end of November 2013. Patients with clinically significant and radiologically proven bronchiectasis were included in the analysis.
Bronchiectasis diagnosis
All patients had a chest high resolution computed tomography (HRCT) scan confirming the presence of bronchiectatic lesions and had symptoms of chronic productive cough. HRCT scans were evaluated by two experienced independent radiologists. Images obtained using 1 mm collimation at full inspiration were reviewed and bronchiectasis was deemed to be present if there was one or more of the following criteria: a bronchoarterial ratio greater than 1, lack of tapering of the bronchi and visualization of bronchi within 1 cm of costal or paravertebral pleura or abutting the mediastinal pleura [11] . Exclusion criteria were patients with a diagnosis of CF (CF transmembrane regulator sequences present on genotyping), an underlying tumoral problem causing the bronchiectatic lesions (post-radiation, secondary immunodeficiency due to chemotherapy or postinfectious due to tumoral obstruction) and patients with traction bronchiectasis caused by interstitial lung disease or sarcoidosis. Each patient with a diagnosis of NCFB was further evaluated for an underlying cause with serum protein electrophoresis, immunoglobulines (IgA, IgE, IgM, IgG, IgG 1-3 ), specific IgE to Aspergillus fumigatus, specific IgG to A. fumigatus, nasal NO measurement, sputum microbiology and ororhinolaryngological evaluation. Spirometry and plethysmography were performed to evaluate impact on lung function. Additional investigations were guided by clinical indication. Postinfectious NCFB was defined as NCFB where there is a clear medical history of a respiratory infection with a distinct isolated pathogen that meant the start of the chronic respiratory complaints or (when no such pathogen could be isolated), a history of recurrent childhood respiratory infections that meant the start of the chronic respiratory complaints. If patients with a primary diagnosis of idiopathic NCFB also had concomitant COPD, they were categorized in the COPD associated NCFB group. COPD was defined using the definition suggested by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). More precisely, patients needed to have symptoms of shortness of breath, chronic cough or sputum production, and a history of exposure to smoke. Patients also needed persistent airflow limitation defined as the presence of a post-bronchodilator FEV 1 /FVC ratio lower than 0.7 (www.goldcopd.org). The initial diagnosis of COPD was made by the general practitioner, the referring respiratory physician or by the outpatient clinic of COPD at the University Hospital of Leuven.
Data collection
The following patient data were collected at inclusion: age, gender, smoking habits (four categories: active, former, passive or never smoker), PA infection status according to the criteria defined by Lee et al. [12] , total number of different bacterial species in retrospective and prospective sputa, presence of PH (defined as a systolic pulmonary arterial pressure of !36 mmHg on echocardiography assuming normal right atrial pressure of 5 mmHg) [13] , exacerbation rate (defined as the use of antibiotic treatment due to two or more of the following symptoms: increase in sputum volume, increase of sputum purulence, dyspnea, cough, hemoptysis or fever more than 38 C), azithromycin use (a minimum dose of 250 mg three times a week during at least 3 consecutive months), other longterm antibiotic use (antibiotic treatment longer than 3 months), SES (based on education level and/or occupation of the head of household and divided by low, middle or high status), spirometry (according to the ATS/ERS guidelines [14, 15] ), number of lobes affected and type of bronchiectasis (based on the worst type present on HRCT: cylindrical, varicous or cystic). For all patients, sputum culture results, therapy use and death were assessed each six months. If death occurred, the patient file was reassessed to identify cause of death mentioned in the patient file.
Ethical committee
Approval was obtained from the local ethical committee of UZ Leuven, Belgium (B51060 e B32220084152) and was registered at ClinicalTrial.gov (NCT01792427).
Statistics
Data were expressed as mean with standard deviation (SD) or median with 25%e75% interquartile range (IQR) based on the distribution of the data. For percent survival and presentation of the figures on total mortality and etiology mortality subanalysis, a KaplaneMeier analysis was performed with a log-rank test to compared different etiology subgroups and the curves presented using GraphPad Prism 5. For the univariate mortality analysis, Cox proportional hazard regression analysis was used to estimate hazard ratios (HR) and their 95% confidence intervals (CI) of several parameters possibly predicting NCFB mortality. For multivariate analysis of factors associated with mortality, a multivariate Cox regression analysis was performed. Variables that were significant in the univariate model were included in the multivariate analysis. Analysis was performed using SAS 9.3 and GraphPad Prism 5. P-values were considered to be significant if lower than 0.05 and twotailed testing was performed.
Results
Patient characteristics
In total 245 patients with a median follow-up of 5.18 years (IQR 4.17e6.38) were included. Patient characteristics are shown in Table 1 .
Univariate mortality analysis
Overall mortality in NCFB patients who had a median followup of 5.18 years was 20.4% (50 deaths, 195 survivors; Fig. 1 ).
Etiology subanalysis showed significant differences between the different causes ( Fig. 2) . Patients with bronchiectasis who had associated chronic obstructive pulmonary disease (COPD) had the worst outcome of all NCFB patients. During the median follow-up of 5.18 years, 55% of the COPD associated NCFB died. Over the median 5.18-year follow-up, 14% of the patients with idiopathic NCFB and 16% of the postinfectious NCFB died. In the miscellaneous group 12% died over the follow-up period. This group includes anatomic malformations, immunodeficiencies, rheumatic disease, primary ciliary dyskinesia (PCD), allergic bronchopulmonary aspergillosis (ABPA), a 1 -antitrypsin deficiency, vasculitis and inflammatory bowel disease. For the larger subgroups in the miscellaneous group (rheumatic disease, ABPA and immunodeficiency), we found that 20% of the patients with rheumatic disease, 11% of the patients with an underlying immunodeficiency and 13% of the ABPA NCFB patients died over the median follow-up period of 5.18 years.
Subanalysis showed significantly different mortality curves in patients with different age, gender, smoking habits, chronic PA colonization (PACC) status (using the criteria defined by Lee et al.) [12] , increased total number of different bacterial species in all collected sputa, spirometric values, radiological severity and extent of disease (Table 2) . A trend was seen for SES, PH and long-term antibiotic use but no significance for exacerbation rate (Table 2 ). When we accounted for the duration of azithromycin use, results remained not significant (p Z 0.97).
Multivariate analysis
Multivariate Cox regression analysis could identify three significant factors associated with higher mortality (Table 3) . Age was associated with a higher mortality (HR Z 1.045; 95% CI 1.01e1.08; p Z 0.004) with a parameter estimate of 0.044. Increasing number of lobes affected were also significantly associated with mortality (HR Z 1.53; 95% CI 1.11e2.09; p Z 0.009) with a parameter estimate of 0.42. A third significant factor for higher mortality in the multivariate analysis was the presence of COPD associated NCFB (HR Z 2.12; 95% CI 1.04-4.30; p Z 0.038) as compared to other etiologies, even when omitting spirometric values from the analysis (as they might interact with COPD) (HR Z 2.20; 95% CI 1.15e4.21; p Z 0.017). Finally, a trend was seen when never smokers were compared to active smokers (HR Z 2.55; 95% CI 0.96e6.79; p Z 0.06).
Causes of death
The majority of deaths were respiratory related (58%; n Z 29; respiratory failure, most frequently due to respiratory infection) or cardiovascular (16%; n Z 8; acute myocardial infarction, rupturing aneurysm, arrhythmia, cardiac failure). For some patients (12%; n Z 6) no clear cause of death was noted in the clinical records. Other causes were neurological (4%; n Z 2; craniocerebral trauma and stroke), gastrointestinal (2%; n Z 1; pancreatic tumor), nephrological (2%; n Z 1; acute kidney failure), haematological (2%; n Z 1; leukemia), euthanasia (2%; n Z 1) and intoxication (2%; n Z 1; alcohol). Table 1 Patient characteristics: For socio-economic status (n Z 189) and PH (n Z 117) we did not have data from all patients. Data are expressed as median with IQR or mean with standard deviation. All antibiotic treatment was given for at least 3 months. Colistimethate was inhaled. The bacteria isolated in sputa mentioned in the table are the most relevant bacteria with a prevalence of more than 5%. The postinfectious causes were tuberculosis (n Z 23), childhood recurrent infections without a clear pathogen (n Z 18), Mycobacterium avium complex (n Z 3), invasive aspergillosis (n Z 2), HIV (n Z 1), childhood measles pneumonia (n Z 1) and severe childhood diphtheria (n Z 1). The 'miscellanous' group includes a 1 -antitrypsin deficiency (n Z 2), vasculitis (n Z 3), inflammatory bowel disease (n Z 5), anatomic malformations (n Z 3), PCD (n Z 8), rheumatic disease (n Z 25), immunodeficient (n Z 18) and ABPA (n Z 15). ABPA Z Allergic Broncho-Pulmonary Aspergillosis; COPD Z chronic obstructive pulmonary disease; F Z Female; FEV 1 Z Forced Expiratory Volume in one second; FVC Z Forced Vital Capacity; IQR Z Interquartile range; M Z Male; NCFB Z Non-cystic fibrosis bronchiectasis; PCD Z Primary Ciliary Diskinesia; PH Z Pulmonary Hypertension; TMP/SMX Z trimethoprim/sulfamethoxazole. Pseudomonas aeruginosa status was categorized according to the criteria by Lee et al. [12] . 
Discussion
Our results show that during the analyzed period, 20.4% of the patients died, with more deaths amongst NCFB patients with associated COPD. The majority of deaths were due to respiratory failure. Univariate analysis showed higher mortality according to age, gender, smoking history, PA status, spirometry, radiological extent/severity, total number of sputum bacteria and underlying etiology. Multivariate analysis resulted in the following risk factors associated with higher mortality: age, number of lobes affected and COPD associated NCFB.
Our analysis with a median follow-up of 5.18 years showed a mortality of 20.4%. These percentages are in line with our previous cross-sectional retrospective analysis and slightly higher than results from the prospective analysis by Loebinger et al. where the 4-year mortality was 9% and the 8.8-year mortality 16.5% [9] . However, the population studied by Loebinger and colleagues shows a low prevalence of COPD as 77% were never-smokers and less than 4% had emphysema on HRCT [9] . When we analyze the survival curves of the idiopathic, postinfectious and other etiologies, we can perceive that these are in line with the data of Loebinger et al. Mortality of our NCFB patients (even the best performing etiological subgroups) is still higher than the general population in Belgium, where a mortality of 9.66& and 9.51& was seen in 2006 and 2007 respectively [16] . We speculate that the vicious cycle of inflammation, infection and structural damage with inappropriate mucus clearance increases the chances that an infection can lead up to severe respiratory insufficiency as compared to the general population, causing excess mortality.
The higher mortality in older, male and smoking patients was previously acknowledged by several authors [4e7,9]. One possible explanation is the fact that the COPD patients were predominantly male. We also found that active and ex-smokers were predominantly male whereas never smokers were predominantly female. After multivariate correction, age was still significant a factor associated with higher mortality. Apart from the logic increase in mortality with increasing age, another contributing factor might be the overall lower compliance in older patients [17, 18] . Whether closer follow-up or better patient education might improve compliance and therefore decrease mortality requires further research.
Loebinger et al. could not assess differences in mortality rates among the different etiologies as the numbers in the several subgroups were too small [9] . Our larger group allowed subanalysis, showing higher mortality rates for patients with associated COPD, even after multivariate analysis. Whether COPD associated bronchiectasis is a distinct COPD phenotype, cannot be concluded from our study as we did not compare COPD patients without bronchiectasis. However, our data add to previous research suggesting that COPD with bronchiectasis is different from ethambutol (n Z 7), TMP/SMX (n Z 5), amoxicillin clavulanate (n Z 1), moxifloxacin (n Z 4), isoniazid (n Z 5) bronchiectasis in other circumstances [19e21] . The higher mortality might be attributed to the fact that these patients have more severe and more frequent exacerbations, higher degree of airway inflammation, lower lung function and increased colonization [19, 22, 23] . It is also possible that the diagnosis of bronchiectasis is delayed in NCFB patients with COPD as the COPD itself can explain the majority of their symptoms. Many less severe COPD patients will be managed in the community but still may have bronchiectasis and COPD [22] . Recent work by MartinezGarcia and colleagues evaluated the impact of bronchiectasis on COPD, approaching this problem from a COPD population perspective. They clearly show that bronchiectasis was associated with an independent risk of allcause mortality in patients with COPD. In their analysis, COPD alone had a mortality of 9.3% whereas our NCFB patients without concomitant COPD had a mortality of 13.3%. More importantly, the combination of COPD and NCFB had similar high mortality rates as our data with a death rate of 37.8% in their study and 55% in our analysis. This suggests that it is not the NCFB or the COPD alone that causes excess mortality, but the combination of both [24] . These high mortality rates and the diagnostic delay often seen in NCFB with concomitant COPD imply that COPD patients with symptoms suggestive of bronchiectasis, such as frequent infectious exacerbations or chronic mucopurulent/purulent expectorations, need further investigation via HRCT.
Multivariate analysis also underlined that the extent of the disease is a risk factor for higher mortality. Extent of the bronchiectasis was a very significant factor in the paper by Loebinger and colleagues but they did not assess HRCT scored in a multivariate way [9] .
NCFB patients with an underlying rheumatological disease also had a high mortality of 20% as opposed to most other NCFB etiologies, with the exception of COPD associated NCFB. Swinson et al. previously found that the presence of bronchiectasis in rheumatological disease may be clinically relevant. Patients with rheumatological disease and bronchiectasis were 7.3 times more likely to die during Table 2 Univariate analysis of factors associated with survival: For socio-economic status (n Z 189) and PH (n Z 117) we did not have data from all patients. For non-continuous data, we displayed the classes how they were analyzed. Therefore the hazard ratio reflects the increase for each class increase. M/H Z Middle/High; n Z number; V/C Z Varicous/Cystic; vs Z versus. 
a 5-year follow-up period than the general population, five times more likely to die than those with rheumatological disease alone and 2.4 times more likely to die than those with bronchiectasis alone [25] . One explanation may be the increased risk for respiratory infections associated with immunomodulatory therapy [26, 27] . Another explanation might be the lower FEV 1 in coexisting NCFB and rheumatological disease as opposed to other NCFB patients [25] . This is in line with our previous data, suggesting that rheumatological disease severity scores inversely correlate with lung functional parameters [26] . The lack of association between mortality and SES in the univariate analysis is somewhat hampered by the lack of data. We only had sufficient SES data from 196 patients. There is however a trend towards significance comparing low to middle class status. This is in line with bronchiectasis data from New Zealand, showing that socio-economic deprivation had a negative impact on survival [6] .
We further found a higher mortality in patients with PACC and in patients with number of different bacteriological species present in sputum in the univariate analysis. We know from literature that PA infection is more prevalent in patients with more severe bronchiectatic disease and causes lower quality of life and worse lung function [27, 28] . PACC is linked with accelerated decline in lung function, more severe exacerbations and higher systemic inflammation [29, 30] . Although PACC was not significant in our multivariate model (possibly due to an overadjusted model), PA infection and PACC are important in NCFB. Our univariate analysis showed a parameter estimate of 0.47 for each increase in Pseudomonas colonization class using the criteria of Lee et al. [12] The importance of PACC was recently confirmed by Martínez-García and colleagues, using PACC as an element of their bronchiectasis FACED severity score [31] . This was simultaneously confirmed by Chalmers et al. in their Bronchiectasis Severity Index [32] . It is therefore important to stay vigilant for the appearance of PA in sputa using regular sputum cultures and timely eradication. It is not clear if first acquisition of PA in NCFB is different from CF, but recent research by De Soyza and colleagues suggests that (in contrast to CF) cross-infection is rare in NCFB patients [33] .
Recently, two scoring systems were published addressing the severity of bronchiectasis. The FACED score is an easy tool that scores 7 points using 5 dichotomized variables to predict mortality and includes FEV 1 , age, PACC, number of lobes affected and shortness of breath [31] . The Bronchiectasis Severity Index predicts both the chance of future hospitalization and mortality and has been validated in other centers around Europe. For mortality they found that older age, lower FEV 1 , prior hospitalization and three or more exacerbations were of significant importance [32] . Both models show that the majority of the factors we found in our univariate analysis play a role in predicting mortality and they are excellent tools to use in daily clinical practice. However, both studies did not investigate the importance of the underlying etiology or associated conditions into their model. We add that associated COPD might play a pivotal role in predicting mortality, but further research with larger populations is needed. Although PH is a known risk factor for mortality and the percentages of deaths were higher in the patients with PH (42%) versus without PH (28%), there was no significant difference in terms of mortality [34] . This might be hampered by the lack of echocardiographic data in 130 patients. Not only has research shown a high prevalence of PH in COPD patients [35, 36] , but PH is also known to be of importance in NCFB as right ventricular dysfunction and right ventricular dimensions are greater in cystic NCFB and are positively correlated with systolic pulmonary artery pressure and negatively correlated with partial pressure of oxygen in arterial blood. In more severe NCFB, there is an impaired perfusion with more capillary bed destruction and left-to-right shunt, leading to impaired cardiac function and pulmonary gas exchange [37] .
There was no significant difference in mortality whether NCFB patients were taking azithromycin or not. To our knowledge, the effect of azithromycin on mortality has not been assessed previously. An improvement of exacerbation rate, HRCT score and lung function were observed in retrospective studies [38, 39] , which was recently confirmed by several double-blind, placebo-controlled trials [40, 41] . The low number of patients, duration of therapy and lack of a control population in our study limits this subanalysis. More research is needed to establish the effect of azithromycin on mortality in NCFB.
Although women are usually predominant in NCFB series, we saw an equal distribution between men and women. This equal distribution is caused by the predominantly male COPD group, whereas the idiopathic and postinfectious bronchiectasis were predominantly female.
One limitation of our study might be the overadjusted multivariate model as we included all univariate significant results in the multivariate model, adding ten variables to the model having only 50 events. To analyze stability of the significant and non-significant variables, we have omitted certain variables in a second analysis (data not shown). The omission of spirometric values (as they might have an interaction with COPD) and number of bacteria in sputum, showed no change in significance of the variables in the multivariate Cox regression model and little change in HR of the variables. Nonetheless, overadjustment is possible and might underestimate the number of multivariate significant variables.
Another limitation is the absence of a severe respiratory condition in a large percentage of our population, given the rather low number of exacerbations and an overall good lung function. This might account for the absence of multivariate significance of PACC, number of exacerbations and FEV 1 in the mortality analysis, whereas other groups have found these factors to be of significant importance [31, 32] . Another reason for the absence of PACC in the multivariate analysis is the significant association we found between number of lobes and PA status (data not shown).
A third limitation might be the fact that some of the patients needed long-term antibiotic treatment for several reasons (treatment for ABPA, Aspergillus or (non)-tuberculous Mycobacteria). Univariate analysis showed that adding these patients to the patients receiving chronic azithromycin therapy, showed a near-significant trend towards a lower mortality. We did not exclude these patients in our cohort as these patients were in a clinically stable state and exclusion of these patients might give a selected view of the overall NCFB population. These results suggest that adequate antibiotic treatment based on underlying infectious cause or adequate use of long-term macrolide treatment may have an impact on mortality, but more prospective research is needed to confirm these findings.
In conclusion, our 5.18-year mortality analysis showed a mortality rate of 20.4%. Variables associated with an increased probability of mortality in patients with NCFB were age, gender, smoking habits, PACC status, increased total number of different bacterial species in all collected sputa, spirometric values, radiological severity, extent of disease and COPD associated NCFB. Multivariate risk factors associated with lower survival are increasing age, number of lobes affected and COPD associated NCFB.
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